Pumitamig

普密妥米单抗

Report date: 2026/05/23 20:00:57

Base Information

Drug NamePumitamig
Drug Alias NamePM8002PM-8002BNT-327BMS-986545
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionVascular endothelial growth factor A inhibitorsProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1Vascular endothelial growth factor A
Therapy Area/IndicationsEsophageal adenocarcinomaMetastatic breast cancerGastroesophageal Junction Neoplasms +[22] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[41] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator Companies +[1]  N/A
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyBristol-Myers Squibb (China) Investment Co LtdDuality Biologics (Suzhou) Co Ltd +[10] 
Inactive CompaniesN/A
Active IndicationsEsophageal adenocarcinomaMetastatic breast cancerGastroesophageal Junction Neoplasms +[21] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A